Open AccessBRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Author(s) -
Edwin Yau
Publication year - 2021
Publication title -
precision cancer medicine
Language(s) - English
Resource type - Journals
ISSN - 2617-2216
DOI - 10.21037/pcm-2020-mnsclc-06
Subject(s) - mutant , targeted therapy , cancer research , oncology , medicine , cancer , biology , gene , genetics